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A percutaneous pulmonary valve-in-valve (PPVIV) implantation in small surgical tis-
sue valves may be limited due to the valve's initial diameter. Fracturing of the valve's
integrity by high-pressure balloons may enhance the diameter and facilitate subse-
quent PPVIV with a large valve. To the best of our knowledge, the Trifecta® valve
seemed not to be accessible for fracturing. We report a case of successful 19-mm
Trifecta valve fracturing, followed by PPVIV using a 26-mm Edwards SAPIEN 3 valve
in pulmonary position. By repetitively using a high-pressure balloon 5 mm larger than
the labeled valve size, we were able to fracture the valve's integrity and implant a
26-mm valve thereafter. Therefore, Trifecta valve appears to be suitable for valve
ring fracturing and subsequent PPVIV in certain patients.
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1 | INTRODUCTION
The Trifecta® valve, a trileaflet polyester-covered titanium stented
pericardial valve, is designed for placement in the aortic position.1
Some Trifecta valves have been implanted in pulmonary valve posi-
tion.2 Today, a failing bioprosthesis can be corrected via transcatheter
valve-in-valve (VIV) therapy, which is also an option for children.
Expanding a degenerated and stenotic bioprosthetic valve to a large
diameter may not only have an immediate impact on pulmonary artery
(PA) hemodynamics but also trigger long-term consequences for
transcatheter valve durability.
2 | CASE REPORT
We report on an eight-year-old boy with pulmonary atresia and sub-
aortic ventricular septal defect (VSD) and multiple major
aortopulmonary collaterals (MAPCAs). His first surgical treatment com-
prised MAPCA unifocalization, VSD closure, and pulmonary valve
implantation using a Matrix-P-Plus-valve. Due to progressive valve
degeneration, he underwent pulmonary valve replacement with a Tri-
fecta valve (inner diameter 19 mm) in pulmonary position 2 years later.
Unfortunately, within 4 years, the Trifecta valve also exhibited
increasing degeneration and combined pulmonary valve malfunction.
Cardiac MRI-examinations revealed pulmonary valve insufficiency, a
regurgitation fraction of about 40%, and a rapidly increasing right ven-
tricular (RV) diameter of >140 ml/m2 end-diastolic RV volume.
The boy presented clinically in NYHA III. Subsequent catheter
examination revealed a minimal pulmonary valve diameter of 14 mm
(Figure 1a,b). The RV pressure was 55 mmHg under deep conscious
sedation. An additional left PA stenosis was initially handled with a
Cheatham Platinum (CP)-stent®.
For safety reasons, we decided to perform a percutaneous pulmo-
nary valve-in-valve (PPVIV) in two steps. After a coronary angiography
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F IGURE 1 (a) and (b) Pulmonary trunk
with stenotic and regurgitant 19-mm
Trifecta® valve in oblique anatomic position.
Minimal inner pulmonary valve diameter
measures between 17 and 14 mm ((a) 30 left
anterior oblique, (b) lateral 90 view). (c) and
(d) Right ventricular outflow tract with
pulmonary trunk and main pulmonary arteries.
CP-stents® are placed in the left main
pulmonary artery and above the Trifecta
valve. A small notch caused by the Trifecta
valve ring remains visible. ((c) 30 left anterior
oblique, (d) lateral 90 view)
F IGURE 2 (a) and (b) Pulmonary valve
dilatation with a 24-mm Atlas Gold® balloon
under high pressure up to 24 atm. Two stent-
braces broke up during this procedure. Post-
intervention diameter is increased to 24 mm
with the right-ventricular outflow tract
unimpaired. ((a) 30 left anterior oblique,
(b) lateral 90 view). (c) and (d) Second
CP-stent® placed above the first one to
stabilize and enlarge the right-ventricular
landing zone. Afterwards, a 26-mm Edwards
Sapien 3 valve was implanted. No
parvasation or valve regurgitation is visible.
The resulting inner diameters are 24 and
25 mm, respectively. ((c) 30 left anterior
oblique, (d) lateral 90 view)
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excluded an anatomic proximity to the right ventricular outflow tract
(RVOT), we prestented the RVOT by using a 28-mm covered eight-zig
CP-stent (NuMED Inc, Hopkinton, NY) (Video S1). Then, we "broke
apart" the Trifecta® valve's integrity using a 24-mm high-pressure bal-
loon (HPB) (Atlas Gold, Bard Temple) with 20 atm in two attempts.
During this procedure, the minimal pulmonary valve diameter
increased from 14 to 18 mm. RV pressure decreased to 40 mmHg;
however, a residual notch caused by the Trifecta valve ring remained
(Figure 1c,d, video S2).
In the second step, 8 weeks later, we repeated the HPB dilatation
using the same balloon size, this time up to 24 atm. We thus managed
to increase the minimal PA diameter at the level of the valve ring to
24 mm with an unimpaired RVOT to optimize hemodynamics and to
facilitate subsequent redo PPVI (Figure 2a,b, video S3). As two stent-
braces broke, a second CP-stent was put in place via a 24-mm VACS
III balloon (OSYPKA, Rheinfelden, Germany). Consequently, the
RVOT-landing zone was stabilized and enlarged up to 25.5 mm. We
then conducted the PPVIV using a 26-mm Edwards SAPIENS three-
valve Edwards (Lifesciences, Irvine, CA) and achieved full balloon infla-
tion. Our final angiography revealed an inner valve diameter of 25 mm
without paravasation or valve-insufficiency (Figure 2c,d). The RV-
pressure was 26/0–5 mmHg. Follow-up echocardiographic examina-
tions, 4 and 20 weeks later, showed laminar flow in RVOT and PA
(vmax of 1.3 m/s). His physical condition improved to NYHA I soon
after intervention.
3 | DISCUSSION
To the best of our knowledge, this is the first detailed report on a suc-
cessful PPVIV after fracturing a Trifecta valve and enlarging the diam-
eter from 14 to 25 mm for excellent hemodynamics.
There is evidence that balloon-initiated valve fracturing is fea-
sible for several different valves to facilitate transcatheter VIV-
implantation.3,4 Shahanavaz et al. showed in a multicenter study in
37 patients intentional valve fracturing in the pulmonary position.5
in vitro bench testing demonstrated successful fracturing of the
valve's ring for the following surgical valves. For example, the
Mitroflow, Magna, Magna Ease, Mosaic, and Biocor Epic.6 Allen
et al. took the standard HPB approach up to 24 atm (exceeding
the manufacturer's rated burst pressures) but only 1 mm larger
than the labeled valve size in his investigation. However, in this
setting, the Trifectas titanium ring maintained integrity and the
balloon burst (employing 19- and 21-mm valves). That valve was
therefore not considered breakable.3 In a computerized model,
Capelli et al., however, showed that inflation force is not just
about balloon pressure, concluding that balloon diameter has a
greater impact on the expansion force than inflation pressure.6
In our patient, we used an HPB diameter applying the same maxi-
mum pressure but substantially exceeding the labeled valve ring size
of about 5 mm. This approach finally enabled us to fracture the valve's
integrity. The covered CP-stent may have protected the balloon from
bursting caused by the rigid titanium ring.
There have been many reports on clinical VIV-implantation
inside failed bioprosthetic surgical valves in aortic position since
the first clinical case by Wenaweser et al. was published in
2007.7,8 It is generally accepted that transcatheter VIV-
implantation for failed bioprosthetic heart valves is a promising
alternative to surgery.9 However, clinicians need to consider that a
valve's design can trigger complications. The Trifecta valve, with
its externally mounted leaflets, ensures close proximity between
proximal valve tissue and the coronary ostia. A coronary-ostium
occlusion has been described in aortic position in conjunction with
VIV-implantation.10
Apart from the aortic side, there is little information about VIV
implantation inside failed bioprosthetic surgical valves in pulmonary
position3 Gillespie et al. reported the largest summary in 2012.11 In
their retrospective analysis of eight centers in the United States
between 2007 and 2012, a cohort of 104 patients (3–63 years)
underwent a VIV implantation using a Melody valve with various
types of bioprosthetic valves, for example, the Carpentier-Edwards
Perimount and Medtronic Hancock Conduit. They reported a high
rate of success associated with excellent short-term outcomes
involving those valve types, but no fracturing of the valve rings was
mentioned.
4 | CONCLUSION
We could successfully demonstrate that the Trifecta valve can be
augmented via HPB dilatation for subsequent PPVIV. By using a
substantially larger HPB repeatedly and under prestenting protec-
tion with a covered stent, we were able to fracture the titanium-
enforced valve ring's integrity without any complications, and put
a big enough valve in place thereafter. This procedure, however,
depends on the anatomic situation, and is therefore only applicable
for a small patient cohort. Valve fracturing with such a balloon
oversizing is only suitable in pulmonary position, as the risk may
be too high for injuries of structures nearby, for example, in aortic
position Transcatheter aortic valve replacement (TAVR). Addition-
ally RVOT and PA need to have an appropriate size for such a bal-
loon. To avoid a dissection we recommend the use of a covered
stent.
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